Cardiology overview electrophysiology: Difference between revisions

Jump to navigation Jump to search
 
(2 intermediate revisions by the same user not shown)
Line 1: Line 1:
{{Cardiology overview}}
{{Cardiology overview}}
{{CMG}}
{{CMG}}
==Brugada syndrome==
* The [[Brugada syndrome]] manifests as ST elevation with a [[right bundle branch pattern]] in the right precordial leads. Is treated with implantation of an [[AICD]].


==STEMI and Arrhythmias==
==STEMI and Arrhythmias==
Line 14: Line 11:


==Atrial Fibrillation==
==Atrial Fibrillation==
===Cardioversion===
* In a patient with new onset atrial fibrillation, an attempt at cardioversion should be made. The patient should be anticoagulated with Coumadin for three weeks before the cardioversion and four weeks after the cardioversion. The anticoagulation after the cardioversion is due to the electrical mechanical dissociation that occurs in these patients.
===Anticoagulation===
===Anticoagulation===
* Patients with a [[CHADS2 score]] of two or higher should be anticoagulated with [[warfarin]].  Some clinicians believe that any patient with [[congestive heart failure]] should also be anticoagulated with [[warfarin]].
* Patients with a [[CHADS2 score]] of two or higher should be anticoagulated with [[warfarin]].  Some clinicians believe that any patient with [[congestive heart failure]] should also be anticoagulated with [[warfarin]].
Line 56: Line 51:
==QT prolongation==
==QT prolongation==
* QT prolongation can be treated with metoprolol
* QT prolongation can be treated with metoprolol
==WPW==
===Complications===
These patients are at risk of rapid conduction of atrial fibrillation and VT / VF
===Treatment===
* EP study and RF ablation of the bypass tract
* Do not use drugs that might block [[AV node]] and send conduction down accessory pathway


==References==
==References==

Latest revision as of 01:06, 4 November 2011

Cardiology Overview

Home

Acute Coronary Syndromes

Antiplatelets and antithrombins

Cardiomyopathy

Congenital heart disease

Electrophysiology

Heart failure

Hypertension

Imaging

Invasive cardiology

Pericardial disease

Peripheral arterial disease

Pharmacology

Pregnancy

Preoperative evaluation

Prevention

Pulmonary hypertension

Stable angina

Valvular heart disease

Venous thromboembolism

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

STEMI and Arrhythmias

Implantable Cardiac Defibrillator

  • Should not be implanted within 40 days of STEMI
  • A patient should wear a defibrillator vest while awaiting AICD implantation
  • Amiodarone improves CV survival but not all cause survival in patients with an LVEF of <40%
  • If someone with an ICD has refractory arrhythmias then radiofrequency ablation of the VT focus can be attempted
  • Sotalol also reduces the frequency of shocks in patients with CAD

Atrial Fibrillation

Anticoagulation

Anticoagulation based on the CHADS2 score

The following treatment strategies are recommended in the table below entitled Anticoagulation based on the CHADS2 score:[1][2]

Score Risk Anticoagulation Therapy Considerations
0 Low Aspirin Aspirin daily
1 Moderate Aspirin or Warfarin Aspirin daily or INR to 2.0-3.0, depending on factors such as patient preference
2 or greater Moderate or High Warfarin INR to 2.0-3.0, unless contraindicated (e.g. clinically significant GI bleeding, inability to obtain regular INR screening)

Rate Control vs Rhythm Control

  • Rhythm control offers no benefit over rate control in survival
  • Rate control is very important in preventing the tachycardia cardiomyopathy syndrome. Patients who are hyperthyroid should be treated with Lopressor until they are euthyroid.
  • Dronedarone reduces hospitalization for atrial fibrillation by about a quarter

Radiofrequency Ablation

  • A complication of radio frequency ablation is left atrial tachycardia or flutter. This complication may itself require treatment.
  • Anticoagulation should be continued after radiofrequency ablation.
  • In patients who have a rapid ventricular response rate in atrial fibrillation and who develop a tachycardia induced cardiomyopathy, AV junctional ablation can be undertaken with permanent pacemaker placement.

QT prolongation

  • QT prolongation can be treated with metoprolol

WPW

Complications

These patients are at risk of rapid conduction of atrial fibrillation and VT / VF

Treatment

  • EP study and RF ablation of the bypass tract
  • Do not use drugs that might block AV node and send conduction down accessory pathway

References

Template:WS Template:WH